Back to the future: proceedings from the 2010 NF Conference.

Am J Med Genet A 2011 Feb 22;155A(2):307-21. Epub 2010 Dec 22.

St. Mary's Hospital, University of Manchester, Manchester, UK.

The neurofibromatoses (NF) encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect 100,000 Americans; over 2 million persons worldwide; and are caused by mutation of tumor suppressor genes. Individuals with NF1 in particular may develop tumors anywhere in the nervous system; additional manifestations can include learning disabilities, bone dysplasia, cardiovascular defects, unmanageable pain, and physical disfigurement. Ultimately, the NFs can cause blindness, deafness, severe morbidity, and increased mortality and NF1 includes a risk of malignant cancer. Today there is no treatment for the NFs (other than symptomatic); however, research efforts to understand these genetic conditions have made tremendous strides in the past few years. Progress is being made on all fronts, from discovery studies-understanding the molecular signaling deficits that cause the manifestations of NF-to the growth of preclinical drug screening initiatives and the emergence of a number of clinical trials. An important element in fuelling this progress is the sharing of knowledge, and to this end, for over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share ideas and build collaborations. The 2010 NF Conference held in Baltimore, MD June 5-8, 2010 hosted over 300 NF researchers and clinicians. This paper provides a synthesis of the highlights presented at the Conference and as such, is a "state-of-the-field" for NF research in 2010.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.33804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079924PMC
February 2011
94 Reads

Publication Analysis

Top Keywords

2010 conference
8
nf1 includes
4
includes risk
4
conference bringing
4
mortality nf1
4
morbidity increased
4
bringing professionals
4
increased mortality
4
risk malignant
4
annual conference
4
treatment nfs
4
foundation convened
4
today treatment
4
cancer today
4
malignant cancer
4
convened annual
4
severe morbidity
4
deafness severe
4
unmanageable pain
4
build collaborations
4

Similar Publications